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arfarin and related coumarin-
based anticoagulants are the 
mainstay of pharmacological 
management for the long-term 
prevention of thromboembolism. It is 
estimated that over 1 million residents 
in the United Kingdom take warfarin; 
in excess of 20 million prescriptions 
for the anticoagulant are dispensed 
each year in the United States of 
America. Despite recent advances in 
the development of novel, alternative, 
oral antithrombotics it is likely that 
coumarins will be used widely for at 
least the next decade.
Mechanism of Action
Coumarins inhibit the posttranslational 
carboxylation of glutamate residues 
on proteins dependent on vitamin K, 
including coagulation factors II, VII, 
IX, and X. This carboxylation process 
is essential for their biological activity 
and requires the reduced form of 
vitamin K. Coumarins inhibit vitamin 
K epoxide reductase, the enzyme 
responsible for the recycling of vitamin 
K. The vitamin K epoxide reductase 
complex 1 (VKORC1) gene has been 
identiﬁ  ed only recently [1] and this 
has permitted study of the effect 
of polymorphisms on sensitivity to 
coumarins. 
The metabolism of warfarin 
depends principally upon the hepatic 
microsomal enzyme P450 2C9 
(Cyp2C9), which catalyses degradation 
of the more potent S enantiomer to 
inactive metabolites.
Variations in the Anticoagulant 
Effect
Coumarins have very few side effects. 
However, by far the most common 
unwanted effect, abnormal bleeding, 
may be lethal. Overall, the rate of 
life-threatening bleeding is around 
two per 100 patient years and more 
minor bleeding is common [2]. This is 
despite the widespread adoption of the 
International Normalised Ratio (INR) 
as the method for standardisation of 
the prothrombin time, the coagulation 
assay used to measure the anticoagulant 
effect of warfarin. 
For most clinical indications, dosing 
is aimed at achieving a target INR of 
2.5 (range 2.0–3.0), which represents 
a level of anticoagulation associated 
with an optimal relationship between 
antithrombotic efﬁ  cacy and bleeding 
risk. However, even with the best 
available management, individual 
patients on warfarin are within the 
target INR range for only 50%–70% 
of the time, on average. Although the 
reasons for this imprecision of dose 
response are often not immediately 
apparent, important contributing 
factors include co-medication with 
interacting drugs [3] and incomplete 
adherence. In addition, the dietary 
content of vitamin K has a measurable 
effect on the INR in patients taking 
warfarin [4].
A Genetic Component to Coumarin 
Sensitivity
In addition to this variation in dose-
response within individuals, the inter-
individual dose range required to 
achieve and maintain the target INR 
is exceptionally wide—for  example, 
in the case of warfarin, a maintenance 
dose of 1 to >10 mg daily. Population 
studies suggested a genetic component 
to coumarin sensitivity; for example, 
people of Chinese origin are more 
sensitive, and African Americans less 
sensitive, than those of European 
ancestry [5,6]. This suggestion has 
now been conﬁ  rmed; a signiﬁ  cant 
proportion of the variation in 
warfarin sensitivity, including the 
variation between ethnic groups, can 
be accounted for by polymorphisms 
within the recently identiﬁ  ed VKORC1 
gene that inﬂ  uence transcriptional 
regulation [7]. This ﬁ  nding 
complements the earlier observation 
that variations in the rate of coumarin 
metabolism, due to the functional 
effects of polymorphisms in Cyp2C9, 
also contribute to individual coumarin 
sensitivity [8], as may polymorphisms in 
the genes for coagulation factors II and 
VII [9]. 
These ﬁ  ndings raise the question of 
whether advances in understanding 
of the pharmacogenetics of oral 
anticoagulant therapy could 
beneﬁ  cially inﬂ  uence clinical practice 
and patient safety by facilitating 
individualised coumarin dosing—
hence reducing bleeding event rates. 
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Answers are just beginning to emerge. 
In a retrospective study, Higashi et al. 
found that variant alleles of Cyp2C9 are 
associated with increased risk of above 
average INRs and longer duration 
to achieve stable dosing (compared 
to wild-type) in patients treated with 
warfarin [10]. Furthermore, patients 
with a variant genotype had increased 
risk of serious or life-threatening 
bleeding, although numbers of events 
were small, dictating caution in 
interpretation. 
A New Study 
Additional evidence of the potential 
for a pharmacogenetic approach to 
reduce bleeding risk from coumarin 
therapy is presented in the current 
issue of PLoS Medicine [11]. Reitsma 
and colleagues used a case-control 
study design to examine the effects 
of the C1173T polymorphism in 
intron 1 of the VKORC1 gene on dose 
requirement and occurrence of severe 
bleeding in subjects treated with the 
long-acting coumarin phenprocoumon 
or short-acting acenocoumarol. A 
signiﬁ  cant effect of genotype on the 
dose required to achieve target INR was 
conﬁ  rmed. In addition, among users 
of phenprocoumon, but not among 
users of acenocoumarol, carriers of 
at least one T allele appeared to have 
an increased risk of bleeding as well 
as greater sensitivity to coumarin. 
However, counterintuitively, the quality 
of INR control appeared to be better in 
subjects on acenocoumarol. 
These intriguing ﬁ  ndings, along 
with those of Higashi and colleagues, 
suggest that further prospective studies 
of the utility of a pharmacogenetic 
approach to improving the safety of 
oral anticoagulation with warfarin are 
justiﬁ  ed. Such studies will of necessity 
be large and should include cost-
effectiveness analyses. They should 
be implemented, but the question 
arises whether their importance may 
be undermined by the licensing for 
long-term use of alternative, novel 
oral anticoagulants that have much 
more predictable dose-response 
characteristics, such as direct thrombin 
inhibitors.  
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